Sentinel Oncology

Sentinel Oncology is a private, preclinical-stage biotech company leveraging its medicinal chemistry expertise to develop targeted small molecule inhibitors for cancers with high unmet need, especially those affecting the brain. Its pipeline features three late-stage preclinical programs, with its lead asset, SOL578 (a Chk1 inhibitor), having entered Phase 1 trials in 2023 via a licensing agreement with PharmaEngine. The company employs a collaborative business model, partnering with pharmaceutical and biotech organizations to advance and commercialize its programs.

Medicinal chemistry expertise focused on designing brain-penetrant small molecule inhibitors, particularly targeting DNA Damage Response (DDR) pathways and mitosis.

Competition is intense in the DNA Damage Response (DDR) inhibitor space and neuro-oncology from larger, well-funded biopharma companies. Sentinel's differentiation lies in its specific focus on designing brain-penetrant small molecules.